Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicentre Trial to Assess the safety and effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion in a Small Vessel (2.25 - 2.5mm diameter)

Next Previous
Trial Profile

A Prospective, Multicentre Trial to Assess the safety and effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion in a Small Vessel (2.25 - 2.5mm diameter)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PLATINUM-SV

    • Most Recent Events

    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2013 Interim results (PLATINUM SV and PLATINUM LL trials ) presented at the 25th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 18 May 2012 Two-year results were reported in a Boston Scientific Corporation media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top